ImClone builds case for higher takeover bid

Published on Thursday 28 August 2008 - 17:40

Summary :
The executives at ImClone have been carefully crunching the numbers for both its pipeline drugs as well as Erbitux as it builds a case that Bristol-Myers Squibb's current offer is far too low to...
Read more

Information source

http://www.fiercebiotech.com/news/frontpage

Website description
Get the latest news on the biotech industry, biotech companies, FDA approval and clinical research. Sign up today for the biotech industry

Articles published on this website : 1 / 7 days - 4 / 30 days

FDA approves prostate cancer drug Degarelix Amgen files for crucial denosumab approval Synta gets $15M milestone from GSK AZ returns rights to two oncology programs OncoGenex shares soar on promising prostate cancer data

Other articles published on other websites on the same day

Hormone Therapy May Speed Prostate Cancer http://www.webmd.com/ Prostate Cancer Screening and Prevention: A Clinical Update for Primary Care Providers http://www.medscape.com/ Cell Genesys Stops Trial For Cancer Vaccine After Deaths http://www.dbtechno.com/ Oilers take aim at prostate cancer http://slam.canoe.ca/ Indian, Pakistani immigrants to the US face prostate, breast cancer risks http://www.dailyindia.com/ Free prostate cancer exams offered http://www.thesunchronicle.com/ Health risk behaviors such as smoking and obesity associated with lower prostate specific antigen awareness http://www.news-medical.net/ Levitra effective on demand http://www.upi.com/ Prostate cancer experts to speak http://www.theacorn.com/